

# Alession Mattesini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1771600/publications.pdf>

Version: 2024-02-01

99  
papers

2,290  
citations

304743

22  
h-index

223800

46  
g-index

116  
all docs

116  
docs citations

116  
times ranked

2473  
citing authors

#	ARTICLE	IF	CITATIONS
1	Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. <i>EuroIntervention</i> , 2015, 10, 1144-1153.	3.2	411
2	Clinical use of intracoronary imaging. Part 2: acute coronary syndromes, ambiguous coronary angiography findings, and guiding interventional decision-making: an expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. <i>European Heart Journal</i> , 2019, 40, 2566-2584.	2.2	189
3	Impact of stent strut design in metallic stents and biodegradable scaffolds. <i>International Journal of Cardiology</i> , 2014, 177, 800-808.	1.7	136
4	Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: a European perspective. <i>EuroIntervention</i> , 2015, 11, 45-52.	3.2	131
5	ABSORB Biodegradable Stents Versus Second-Generation Metal Stents. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 741-750.	2.9	115
6	Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: development and internal validation of the PSP score. <i>EuroIntervention</i> , 2017, 12, 2110-2117.	3.2	114
7	Intravascular lithotripsy for calcific coronary and peripheral artery stenoses. <i>EuroIntervention</i> , 2019, 15, 714-721.	3.2	68
8	Very high-pressure dilatation for undilatable coronary lesions: indications and results with a new dedicated balloon. <i>EuroIntervention</i> , 2016, 12, 359-365.	3.2	67
9	Local and general anaesthesia do not influence outcome of transfemoral aortic valve implantation. <i>International Journal of Cardiology</i> , 2014, 177, 448-454.	1.7	65
10	Inducing Persistent Flow Disturbances Accelerates Atherogenesis and Promotes Thin Cap Fibroatheroma Development in PCSK9 Hypercholesterolemic Minipigs. <i>Circulation</i> , 2015, 132, 1003-1012.	1.6	58
11	Contemporary Approach to Heavily Calcified Coronary Lesions. <i>Interventional Cardiology Review</i> , 2019, 14, 154-163.	1.6	56
12	Intracoronary optical coherence tomography: state of the art and future directions. <i>EuroIntervention</i> , 2021, 17, e105-e123.	3.2	55
13	Absorb bioresorbable vascular scaffold: What have we learned after 5years of clinical experience?. <i>International Journal of Cardiology</i> , 2015, 201, 129-136.	1.7	51
14	Impact of Kissing Balloon in Patients Treated With Ultrathin Stents for Left Main Lesions and Bifurcations. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008325.	3.9	39
15	Bioabsorbable vascular scaffold overexpansion: insights from in vitro post-expansion experiments. <i>EuroIntervention</i> , 2016, 11, 1389-1399.	3.2	35
16	Clinical use of intracoronary imaging. Part 2: acute coronary syndromes, ambiguous coronary angiography findings, and guiding interventional decision-making: an expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. <i>EuroIntervention</i> , 2019, 15, 434-451.	3.2	35
17	Early and midterm outcomes of bioresorbable vascular scaffolds for ostial coronary lesions: insights from the GHOST-EU registry. <i>EuroIntervention</i> , 2016, 12, e550-e556.	3.2	32
18	Bioresorbable vascular scaffold use for coronary bifurcation lesions: A substudy from GHOST EU registry. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 47-56.	1.7	28

#	ARTICLE	IF	CITATIONS
19	Calcium: A predictor of interventional treatment failure across all fields of cardiovascular medicine. <i>International Journal of Cardiology</i> , 2017, 231, 97-98.	1.7	27
20	Tools & Techniques Clinical: Optimising stenting strategy in bifurcation lesions with insights from in vitro bifurcation models. <i>EuroIntervention</i> , 2013, 9, 885-887.	3.2	25
21	Optical coherence tomography guidance for percutaneous coronary intervention with bioresorbable scaffolds. <i>International Journal of Cardiology</i> , 2016, 221, 352-358.	1.7	24
22	1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 440-449.	2.9	23
23	Breve historia de los stents coronarios. <i>Revista Espanola De Cardiologia</i> , 2018, 71, 312-319.	1.2	23
24	Time-related changes in neointimal tissue coverage of a novel Sirolimus eluting stent. <i>Cardiovascular Revascularization Medicine</i> , 2016, 17, 38-43.	0.8	21
25	The DESolve novolimus bioresorbable Scaffold: from bench to bedside. <i>Journal of Thoracic Disease</i> , 2017, 9, S950-S958.	1.4	20
26	Impact of Final Kissing Balloon and of Imaging on Patients Treated on Unprotected Left Main Coronary Artery With Thin-Strut Stents (From the RAIN-CARDIOGROUP VII Study). <i>American Journal of Cardiology</i> , 2019, 123, 1610-1619.	1.6	20
27	Indications and immediate and long-term results of a novel pericardium covered stent graft: Consecutive 5 year single center experience. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 712-719.	1.7	19
28	Biodegradable vascular scaffold: is optimal expansion the key to minimising flow disturbances and risk of adverse events?. <i>EuroIntervention</i> , 2015, 10, 1139-1142.	3.2	19
29	OCT-guided Percutaneous Coronary Intervention in Bifurcation Lesions. <i>Interventional Cardiology Review</i> , 2019, 14, 5-9.	1.6	18
30	A Brief History of Coronary Artery Stents. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2018, 71, 312-319.	0.6	17
31	Optical coherence tomography assessment and quantification of intracoronary thrombus: Status and perspectives. <i>Cardiovascular Revascularization Medicine</i> , 2015, 16, 172-178.	0.8	16
32	Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 560-568.	2.9	16
33	Impact of overlapping on 1-year clinical outcomes in patients undergoing everolimus-eluting bioresorbable scaffolds implantation in routine clinical practice: Insights from the European multicenter GHOST-EU registry. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 812-818.	1.7	15
34	Impact of structural features of very thin stents implanted in unprotected left main or coronary bifurcations on clinical outcomes. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1-9.	1.7	15
35	Absorb vs. DESolve: an optical coherence tomography comparison of acute mechanical performances. <i>EuroIntervention</i> , 2016, 12, e566-e573.	3.2	15
36	Hyperglycemia, acute insulin resistance, and renal dysfunction in the early phase of ST-elevation myocardial infarction without previously known diabetes: impact on long-term prognosis. <i>Heart and Vessels</i> , 2014, 29, 769-775.	1.2	14

#	ARTICLE	IF	CITATIONS
37	Intravascular Imaging to Guide Lithotripsy in Concentric and Eccentric Calcific Coronary Lesions. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 1099-1105.	0.8	14
38	Daily risk of adverse outcomes in patients undergoing complex lesions revascularization: A subgroup analysis from the RAIN-CARDIOGROUP VII study (very thin stents for patients with left main or Tj ETQq0 0 0 rgBT 10 Overlock 10 Tf 50 69)	1.0	10
39	Mechanical ventilation in the early phase of ST elevation myocardial infarction treated with mechanical revascularization. <i>Cardiology Journal</i> , 2013, 20, 612-617.	1.2	13
40	Glycated haemoglobin and long-term mortality in patients with ST Elevation Myocardial Infarction. <i>Journal of Cardiovascular Medicine</i> , 2015, 16, 404-408.	1.5	11
41	Impact of strut thickness on acute mechanical performance: A comparison study using optical coherence tomography between DESolve 150 and DESolve 100. <i>International Journal of Cardiology</i> , 2017, 246, 74-79.	1.7	10
42	Incidence of Adverse Events at 3 Months Versus at 12 Months After Dual Antiplatelet Therapy Cessation in Patients Treated With Thin Stents With Unprotected Left Main or Coronary Bifurcations. <i>American Journal of Cardiology</i> , 2020, 125, 491-499.	1.6	10
43	Intravascular Lithotripsy and Impella Support to Assist Complex LM Angioplasty. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 143-146.	0.8	9
44	Twelve-month outcomes after bioresorbable vascular scaffold implantation in patients with acute coronary syndromes. Data from the European Multicenter GHOST-EU Extended Registry. <i>EuroIntervention</i> , 2017, 13, e1104-e1111.	3.2	9
45	Optical coherence tomography characteristics of in-stent restenosis are different between first and second generation drug eluting stents. <i>International Journal of Cardiology Heart &amp; Vessels</i> , 2014, 3, 68-74.	0.5	8
46	Clinical outcomes of patients with diabetes mellitus treated with Absorb bioresorbable vascular scaffolds: a subanalysis of the European Multicentre GHOST-EU Registry. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 444-453.	1.7	8
47	Thrombus aspiration in elderly STEMI patients. <i>International Journal of Cardiology</i> , 2013, 168, 3097-3099.	1.7	7
48	Comorbidities in stemi patients submitted to primary PCI: Temporal trends and impact on mortality. <i>International Journal of Cardiology</i> , 2013, 167, 3042-3044.	1.7	7
49	A new novolimus-eluting bioresorbable scaffold for large coronary arteries: an OCT study of acute mechanical performance. <i>International Journal of Cardiology</i> , 2016, 220, 706-710.	1.7	7
50	Advancements in Transcatheter Aortic Valve Implantation: A Focused Update. <i>Medicina (Lithuania)</i> , 2021, 57, 711.	2.0	7
51	Chronic total occlusion successfully treated with a bioresorbable everolimus-eluting vascular scaffold. <i>Postepy W Kardiologii Interwencyjnej</i> , 2014, 2, 128-129.	0.2	6
52	Acidemia in severe acute cardiogenic pulmonary edema treated with noninvasive pressure support ventilation. <i>Journal of Cardiovascular Medicine</i> , 2015, 16, 610-615.	1.5	6
53	Post-dilatation after implantation of bioresorbable everolimus- and novolimus-eluting scaffolds: an observational optical coherence tomography study of acute mechanical effects. <i>Clinical Research in Cardiology</i> , 2017, 106, 271-279.	3.3	6
54	Accuracy of the PARIS score and PCI complexity to predict ischemic events in patients treated with very thin stents in unprotected left main or coronary bifurcations. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, E227-E236.	1.7	6

#	ARTICLE	IF	CITATIONS
55	Blood lactate predicts survival after percutaneous implantation of extracorporeal life support for refractory cardiac arrest or cardiogenic shock complicating acute coronary syndrome: insights from the CareGem registry. <i>Internal and Emergency Medicine</i> , 2021, 16, 463-470.	2.0	6
56	Bioabsorbable scaffold optimization in provisional stenting: insight from optical coherence tomography. <i>European Heart Journal Cardiovascular Imaging</i> , 2013, 14, 1149-1149.	1.2	5
57	Acute Insulin Resistance Assessed by the Homeostatic Model Assessment in Acute Coronary Syndromes Without Previously Known Diabetes. <i>Angiology</i> , 2014, 65, 519-524.	1.8	5
58	New Advances in the Treatment of Severe Coronary Artery Calcifications. <i>Cardiology Clinics</i> , 2020, 38, 619-627.	2.2	5
59	Comparison of bioresorbable vs durable polymer drug-eluting stents in unprotected left main (from) Tj ETQq1 1 0.784314 rgBT /Overl	1.7	5
60	Bioresorbable Scaffold Thrombosis. <i>Journal of the American College of Cardiology</i> , 2016, 68, 571-572.	2.8	4
61	Overlapping implantation of bioresorbable novolimus-eluting scaffolds: an observational optical coherence tomography study. <i>Heart and Vessels</i> , 2017, 32, 781-789.	1.2	4
62	Gender Issues in Italian Catheterization Laboratories: The Genderâ€CATH Study. <i>Journal of the American Heart Association</i> , 2021, 10, e017537.	3.7	4
63	Stop adding metal layers: Will bioabsorbable scaffolds become the gold standard for late in-stent restenosis and neo-atherosclerosis?. <i>Cardiovascular Revascularization Medicine</i> , 2015, 16, 124-126.	0.8	3
64	Will Optical Coherence Tomography Become the Standard Imaging Toolâ€forâ€Percutaneous Coronary Intervention Guidance?. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1322-1324.	2.9	3
65	A simple step-by-step approach for proficient utilization of the EchoNavigator technology for left atrial appendage occlusion. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 725-727.	1.2	3
66	Discontinuation of both cangrelor and ticagrelor because of severe dyspnea during primary angioplasty. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 317-319.	1.5	3
67	Prospectively electrocardiogram-triggered high-pitch spiral acquisition coronary computed tomography angiography for assessment of biodegradable vascular scaffold expansion: Comparison with optical coherence tomography. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 436-438.	0.8	2
68	A rapidly growing coronary pseudoaneurysm. <i>Cardiovascular Revascularization Medicine</i> , 2015, 16, 320-321.	0.8	2
69	TCT-419 Usefulness of a scoring system for predicting adverse cardiovascular events in patients undergoing everolimus-eluting bioresorbable scaffolds implantation: the PSP score. <i>Journal of the American College of Cardiology</i> , 2016, 68, B169-B170.	2.8	2
70	An amber signal lights up before the red: do not dismiss it. <i>European Heart Journal</i> , 2018, 39, 303-304.	2.2	2
71	Percutaneous Trans-septal Mitral Valve-in-Ring Implantation Using a Transcatheter Balloon-Expandable Transcatheter Heart Valve With Elective Intra-Procedural Artero-Venous ECMO in a Patient With Severely Reduced Left Ventricular Ejection Fraction. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 174.	2.4	2
72	What Do You Need for Chronicâ€Totalâ€Occlusion Recanalization. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 556-557.	2.9	2

#	ARTICLE	IF	CITATIONS
73	Why can flu be so deadly? An unusual case of cardiogenic shock. Internal and Emergency Medicine, 2020, 15, 679-684.	2.0	2
74	Percutaneous Watchman FLX implantation in a patient with previous mitral valve surgery and large-sized left atrial appendage. European Heart Journal - Case Reports, 2020, 4, 1-2.	0.6	2
75	Atrial Fibrillation and Resistant Stroke: Does Left Atrial Appendage Morphology Matter? A Case Report. Frontiers in Neurology, 2020, 11, 592458.	2.4	2
76	Severe Compression of a Left Main Coronary Stent Implanted Using a Chimney Technique. JACC: Cardiovascular Interventions, 2020, 13, e141-e142.	2.9	2
77	TAVR in patients with hip fracture and severe aortic stenosis: how and when?. Internal and Emergency Medicine, 2021, 16, 1419-1422.	2.0	2
78	The DESolve® novolimus bioresorbable scaffold. Future Cardiology, 2021, 17, 945-951.	1.2	2
79	Thrombus aspiration in ST-elevation myocardial infarction: Does it actually impact long-term outcome?. Cardiology Journal, 2015, 22, 306-314.	1.2	2
80	Prediction of All-Cause Mortality Following Percutaneous Coronary Intervention in Bifurcation Lesions Using Machine Learning Algorithms. Journal of Personalized Medicine, 2022, 12, 990.	2.5	2
81	Continuous renal replacement therapy: Should the cardiologist be able to manage it out of intensive care units?. International Journal of Cardiology, 2011, 150, 233-235.	1.7	1
82	TCT-514 Absorb Vs DESolve: an optical coherence tomography comparison of acute mechanical performances. Journal of the American College of Cardiology, 2015, 66, B210.	2.8	1
83	Bioresorbable Vascular Scaffolds as a Treatment Option for Left Main Lesions. JACC: Cardiovascular Interventions, 2017, 10, 743-745.	2.9	1
84	The Forgotten Art of Balloon Angioplasty. Cardiovascular Revascularization Medicine, 2018, 19, 399-400.	0.8	1
85	Supra-Aortic Vessel Stenting to Stabilize an Embolized Acurate NEOTranscatheter Heart Valve: The Chandelier Technique. Cardiovascular Revascularization Medicine, 2021, 28, 102-104.	0.8	1
86	Long-term echocardiographic findings after TAVR: 5-year follow-up in 400 consecutive patients. Internal and Emergency Medicine, 2021, 16, 1873-1882.	2.0	1
87	EuroCTO Club 2018 meeting: "Experts Live" in Toulouse. EuroIntervention, 2019, 14, e1814-e1817.	3.2	1
88	Early coverage of Bioabsorbable Scaffold after STEMI analysed by 2D and 3D optical coherence tomography. Cardiovascular Revascularization Medicine, 2013, 14, 363-364.	0.8	0
89	Intracoronary Optical Coherence Tomography: Experience and Indications for Clinical Use. Current Cardiovascular Imaging Reports, 2013, 6, 399-410.	0.6	0
90	TCT-512 Bioabsorbable Vascular Scaffold Radial Expansion and Conformation Compared to a Metallic platform: Insights from In-vitro Expansion in a Coronary Artery Lesion Model. Journal of the American College of Cardiology, 2015, 66, B209.	2.8	0

#	ARTICLE	IF	CITATIONS
91	Diagnosis and Evaluation of Stent Thrombosis with Optical Coherence Tomography. <i>Interventional Cardiology Clinics</i> , 2015, 4, 295-307.	0.4	0
92	The long way to better PCI results in diabetic patients. <i>International Journal of Cardiology</i> , 2017, 245, 90-91.	1.7	0
93	Resurrection of a New Old Technique. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e007421.	3.9	0
94	Multivessel Disease Patientsâ€™ Outcome and Second Generation Stent: Is Syntax Still a Valid Score? A RealWorld Study from a Tertiary Center. <i>Acta Medica Academica</i> , 2021, 49, 265.	0.8	0
95	Going through or around the occlusion? All roads lead to Rome. <i>Cardiology Journal</i> , 2021, 28, 355-357.	1.2	0
96	Simulation of flow and shear stress. , 2017, , 68-80.		0
97	OCT for Bioabsorbable Vascular Scaffold. , 2020, , 139-147.		0
98	Optical coherence tomography guidance: when one size does not fit all. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 760-764.	1.2	0
99	Performance of Thin-Strut Stents in Non-Left Main Bifurcation Coronary Lesions: A RAIN Subanalysis. <i>Journal of Invasive Cardiology</i> , 2021, 33, E890-E899.	0.4	0